Can biomedical tech transfer create both goodwill and good wealth? The case for a global fair profit/for profit model Online publication date: Mon, 23-Feb-2009
by Robert Jameson, Daniel Lorence, James Chin, Frank Peo, Luis Gonzales
International Journal of Technology Transfer and Commercialisation (IJTTC), Vol. 8, No. 1, 2009
Abstract: Proposed here as a technology transfer practice, we highlight the adoption of a fair profit/for profit model as a means for sustainable biomedical commercialisation. This model de-emphasises short-term, profit maximisation (full-profit) strategies and highlights the tech transfer advantages of niche markets and localised manufacturing, coupled with proven best practices of medical specialties and focused on global market needs. This model recognises, but is not driven by, local regulatory barriers and minimises or eliminates the development and marketing costs traditionally associated with new medical products in industrialised nations. Such a model can be sustainable and profitable, when adopted as part of a global, controlled-growth commercialisation strategy.
Online publication date: Mon, 23-Feb-2009
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Transfer and Commercialisation (IJTTC):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email email@example.com